[
    [
        {
            "time": "",
            "original_text": "贝达药业点评报告:恩莎替尼申请上市,研发管线进入收获期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩莎替尼",
                    "申请上市",
                    "研发管线",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业点评报告:恩莎替尼申请上市,研发管线进入收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "浙江药企逆势飘红：仿制药一致性评价通过量全国第一",
            "features": {
                "keywords": [
                    "浙江药企",
                    "逆势飘红",
                    "仿制药",
                    "一致性评价",
                    "全国第一"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浙江药企逆势飘红：仿制药一致性评价通过量全国第一",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 5,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报:医保局调结构被数据验证,大破大立下拥抱创新升级",
            "features": {
                "keywords": [
                    "医药生物",
                    "医保局",
                    "调结构",
                    "数据验证",
                    "创新升级"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业周报:医保局调结构被数据验证,大破大立下拥抱创新升级",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]